Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma

Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma

Treatment of metastatic urothelial carcinoma (mUC) after failure with platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) remains controversial. To explore the role of subsequent systemic therapy, medical records from 436 patients who were consecutively treated with chemotherapy for...

Full description

Bibliographic Details
Main Authors: Joohyun Hong, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Biomedicines
Subjects:
urothelial carcinoma
chemotherapy
salvage therapy
clinical trials
Online Access:https://www.mdpi.com/2227-9059/10/8/2005

Internet

https://www.mdpi.com/2227-9059/10/8/2005

Similar Items